Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) shares rose 2.2% on Tuesday . The company traded as high as $19.78 and last traded at $19.60, with a volume of 188,068 shares changing hands. The stock had previously closed at $19.18.

BLCM has been the topic of a number of recent research reports. SunTrust Banks Inc. initiated coverage on shares of Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price target on the stock. Piper Jaffray Cos. reissued a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Zacks Investment Research raised shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Citigroup Inc. raised shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 target price on the stock in a research report on Tuesday, August 9th. Finally, Jefferies Group boosted their target price on shares of Bellicum Pharmacueticals from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Bellicum Pharmacueticals currently has a consensus rating of “Buy” and a consensus target price of $27.00.

The company’s market capitalization is $533.39 million. The stock has a 50 day moving average price of $15.22 and a 200 day moving average price of $11.64.

Bellicum Pharmacueticals (NASDAQ:BLCM) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by $0.04. During the same quarter in the prior year, the business posted ($0.40) earnings per share. Equities research analysts expect that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current year.

In related news, insider David M. Spencer sold 10,000 shares of the stock in a transaction that occurred on Wednesday, July 27th. The stock was sold at an average price of $15.00, for a total value of $150,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, VP Ken Moseley sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total value of $195,000.00. Following the completion of the transaction, the vice president now owns 15,196 shares in the company, valued at approximately $197,548. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned approximately 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent reporting period.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.